Global Health News - Week ending 25 October 2026

WHO reports Bundibugyo outbreak expansion and launch of TUMAINI vaccine trial

WHO's Disease Outbreak News update, citable as 23 October 2026, reported sustained, high level transmission of Bundibugyo virus disease in the Democratic Republic of the Congo, with 9,704 confirmed cases and 4,687 deaths, a crude case fatality ratio of 48.3%, across 66 health zones in eight provinces as of 20 October 2026. Since the previous update on 8 October, 482 additional deaths had been reported, including 307 deaths in communities and 175 deaths in treatment centres, which WHO linked to continued challenges in early case detection and timely access to appropriate care. Kenya had reported nine cases, including one death, all linked to a single imported case cluster, with no evidence of wider community transmission and 135 contacts traced and quarantined, while Nigeria confirmed its first imported case on 20 October in Abuja, becoming the fifth country affected, with 44 contacts identified and monitored. On 23 October, the TUMAINI vaccine trial was launched in Bunia, described as a pivotal phase 2/3 trial of vaccine candidates against Bundibugyo virus, supported by WHO and partners with technical, scientific and operational expertise. WHO also noted that no approved vaccines or specific treatments currently exist for Bundibugyo virus disease, and described the outbreak as the largest Ebola disease outbreak ever recorded in the Democratic Republic of the Congo, irrespective of virus species.

Why it matters: This is essential outbreak, infection prevention, contact tracing and clinical trial literacy, showing why a high fatality pathogen without a licensed vaccine still depends on surveillance, isolation, community engagement and research conducted during an emergency.

Source: WHO, 23 October 2026

World Top Stories

FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

The Food and Drug Administration granted accelerated approval on 19 October 2026 to dostarlimab, sold as Jemperli, for adults with stage II or III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient, as determined by an FDA authorised test for solid tumours. The decision rested mainly on AZUR-1, a multicentre, single arm, open label trial in 154 patients with previously untreated disease, in which response was assessed by endoscopy, rectal MRI and CT imaging, followed by close monitoring for those with a clinical complete response. Among the treated patients, 110 people, or 71%, received dostarlimab alone, received no additional treatment and experienced no disease progression, while the sustained 12 month clinical complete response rate was 47% in the 116 patients evaluable by independent central review. The objective response rate by independent central review was 79%, and the investigator assessed sustained 12 month clinical complete response rate was 68%, with an objective response rate of 82%. The labelling includes warnings for immune mediated adverse reactions, infusion related reactions, complications of allogeneic haematopoietic stem cell transplantation and embryo foetal toxicity, and the review was conducted under Project Orbis with Health Canada, Israel, Swissmedic and the UK Medicines and Healthcare products Regulatory Agency, with priority review and breakthrough therapy designation.

Why it matters: This shows pharmacy and healthcare students how biomarker testing, accelerated approval and international regulatory collaboration can change the treatment pathway for a defined rectal cancer subgroup, and why response definitions and independent review matter when interpreting single arm trial evidence.

Source: FDA, 19 October 2026

FDA approves first antisense treatment for chronic hepatitis B

The Food and Drug Administration approved Hibsago, the generic name bepirovirsen, on 20 October 2026, in combination with existing antiviral therapy, for certain adults with chronic hepatitis B virus infection who do not have cirrhosis. Eligibility described by the agency covers adults who have received hepatitis B antiviral therapy for at least six months, have suppressed virus levels in the blood, and have hepatitis B surface antigen levels of 3,000 IU/mL or less, as determined by an FDA authorised test. The agency described the product as the first FDA approved antisense oligonucleotide for chronic hepatitis B, acting by targeting the genetic instructions the virus uses to make copies of itself and viral proteins, and it also authorised the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic to help select and monitor patients. Across two placebo controlled trials, 24% of patients who received bepirovirsen met the requirements to stop their existing medicine, compared with none who received placebo, and 24 weeks after stopping all hepatitis B treatment, 19% still had the virus under control with hepatitis B surface antigen undetectable in the blood. The product carries a boxed warning for serious liver reactions and low platelet counts, which can increase the risk of potentially life threatening bleeding, and the most common side effects reported, excluding laboratory abnormalities, were injection site reactions, fever, fatigue and headache.

Why it matters: This is a landmark example of a finite treatment strategy in chronic hepatitis B, companion diagnostic use, functional cure as a trial concept, and the balance between a new mechanism and serious safety warnings.

Source: FDA, 20 October 2026

WHO publishes first global assessment of inequalities in noncommunicable diseases

The World Health Organization published its report, State of inequality: noncommunicable diseases and their risk factors, on 20 October 2026, presenting a global assessment of differences between population groups within countries rather than only national averages. The report covers cancer, cardiovascular diseases, chronic respiratory diseases and diabetes, together with tobacco and alcohol use, obesity and unhealthy diets, insufficient physical activity and air pollution. Drawing on national data collected over the past decade, it examines differences in disease burden, prevention and care by age, gender, economic status, education, place of residence, disability status, employment and migration status. The findings reported by WHO include higher rates of hypertension and diabetes among less educated populations in low and middle income countries, lower cervical cancer screening among poorer and less educated women, higher tobacco use among less educated men, and lower access to hypertension diagnosis and treatment and cervical cancer screening in rural populations. An accompanying advocacy brief, The hidden inequalities behind noncommunicable diseases: from evidence to action, sets out how inequality data can be used to strengthen prevention and control, including population wide interventions, better targeting of resources and routine measurement of inequalities.

Why it matters: For pharmacy and healthcare students, this links clinical conditions to social determinants, screening access and service design, and shows why disaggregated data are essential for fair prevention and treatment.

Source: WHO, 20 October 2026

WHO issues first guidance on evidence generation for new tuberculosis diagnostics

The World Health Organization published, for the first time, Guidance on evidence generation for new tuberculosis diagnostics on 21 October 2026, as the third document in its evidence generation series, following guidance on new tuberculosis treatment regimens and on tuberculosis preventive treatment. The guidance is aimed at researchers, developers, funders and other stakeholders, and explains how evidence should be generated so that it can best inform WHO guideline development on new diagnostic tests, sample types and testing strategies. It covers diagnostic accuracy study design, participant selection, sample size and reporting, and also addresses outcomes that matter to patients, values, cost effectiveness, equity, acceptability and feasibility. A new analytical framework in the guidance maps the role of a diagnostic across the clinical pathway and links that role to study design, population, methods and reporting. WHO noted that evidence for new tuberculosis diagnostics has often been insufficient or incomplete, with methodological limitations, exclusion of vulnerable populations, a focus only on accuracy, and incomplete or inconsistent reporting that makes synthesis difficult, and it positioned the guidance alongside its target product profiles for tuberculosis diagnosis and drug resistance detection.

Why it matters: This teaches students that a diagnostic is not judged on accuracy alone, and that study design, equity, feasibility and reporting quality determine whether a test can move from research into a WHO recommendation and routine use.

Source: WHO, 21 October 2026

WHO and ILO launch framework to track social protection for people with tuberculosis

The World Health Organization and the International Labour Organization published a new monitoring and evaluation framework on 21 October 2026 to help countries track progress towards universal social protection inclusive of people with tuberculosis. The framework responds to the social and economic consequences of tuberculosis, including costs linked to accessing and completing care and loss of income and employment, with WHO noting that nearly half, 47%, of people treated for tuberculosis and their households experienced catastrophic costs across countries that have conducted national tuberculosis household cost surveys. It provides a practical way to measure progress towards the commitment made at the 2023 United Nations General Assembly High Level Meeting on tuberculosis, that 100% of people with tuberculosis should have access to a health and social benefits package by 2027, and to identify gaps in coverage and protection. The approach is phased, so it can be applied in countries with different social protection systems, data availability and monitoring capacity, building on existing health and social protection monitoring while progressively strengthening measurement of whether support is timely, adequate and comprehensive. The framework complements the 2024 WHO and ILO guidance on social protection for people affected by tuberculosis and contributes to multisectoral monitoring and accountability through WHO's Multisectoral Accountability Framework to end tuberculosis.

Why it matters: This connects tuberculosis treatment to financial protection, adherence and household impact, a core lesson for students on why medicines alone do not complete tuberculosis care.

Source: WHO, 21 October 2026

Global Diagnostics Coalition calls for collective action to close the diagnostic gap

The Global Diagnostics Coalition convened leaders from government, global health, civil society, industry and partner organisations at the World Health Summit 2026, with WHO publishing its account of the event on 22 October 2026. The central concern was that 47% of the world's population still lacks access to a timely, reliable diagnosis, limiting early detection, treatment and effective care, and weakening universal health coverage, health security and pandemic preparedness. In a video message opening the event, WHO Director General Dr Tedros Adhanom Ghebreyesus emphasised building resilient health systems before crises occur, with capacity to detect and respond to threats while meeting everyday needs. Carol Nawina, Executive Director of CITAMplus, described repeatedly seeking care before receiving diagnoses of HIV, tuberculosis and cancer, and called for diagnostic services to be brought closer to communities, organised around people rather than single diseases, with communities treated as equal partners in shaping services and accountability. An expert panel discussed innovation shaped by country needs, stronger investment, workforce and infrastructure constraints, more effective regulatory pathways, and better data on the health and economic value of diagnostics, while the Coalition reported progress one year after its launch through its three pillars of Illuminate, Champion and Integrate.

Why it matters: For students, this explains why diagnostics are a health system foundation, not an optional extra, and how delayed diagnosis creates repeated visits, avoidable costs and missed treatment opportunities.

Source: WHO, 22 October 2026

FDA approves first once weekly insulin for children with type 2 diabetes

The Food and Drug Administration approved Awiqli, the generic name insulin icodec-abae, as the first once weekly insulin for children with type 2 diabetes, with the FDA approval page updated on 23 October 2026 and the FDA Notable Approvals listing giving the same date. The approval covers paediatric patients aged 10 years and older with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycaemic control, using a long acting insulin analogue given by subcutaneous injection once weekly, following an adult approval for the same condition earlier in 2026. The paediatric decision was based on adequate and well controlled studies in adults together with a single dose study of pharmacokinetic properties in 18 paediatric patients aged 10 years and older, in which first dose absorption was faster than in adults but pharmacometric modelling indicated that blood levels became similar to adult levels after the first few doses. The agency stated that the safety profile is similar to that of other insulin products, with the most common adverse reactions including hypoglycaemia, hypersensitivity reactions, injection site reactions, changes in fat tissue at the injection site, itching, rash, swelling and weight gain. Severe hypoglycaemia was noted as capable of causing seizures, unconsciousness, life threatening complications or death, and the labelling also includes warnings for medication errors and accidental overdose, hyperglycaemia, low potassium levels, and fluid retention and heart failure when used with thiazolidinediones.

Why it matters: This illustrates extrapolation from adult evidence, paediatric pharmacokinetic modelling, adherence implications of weekly versus daily basal insulin, and the safety counselling issues that accompany a differently dosed insulin product.

Source: FDA, 23 October 2026

Lancet publishes phase 3 remibrutinib results in relapsing multiple sclerosis

The Lancet published online on 23 October 2026 the results of REMODEL-1 and REMODEL-2, two identical, randomised, double blind, double dummy, active comparator controlled phase 3 trials comparing remibrutinib with teriflunomide in adults with relapsing multiple sclerosis. The trials were conducted at 407 centres in 46 countries, screened 2,632 patients and randomly assigned 2,007 patients aged 18 to 55 years with relapsing multiple sclerosis, an Expanded Disability Status Scale score of 0 to 5.5, and evidence of recent disease activity. The primary endpoint was annualised relapse rate, and remibrutinib was significantly lower than teriflunomide in both trials, at 0.073 versus 0.112 in REMODEL-1, with a rate ratio of 0.648, and 0.080 versus 0.116 in REMODEL-2, with a rate ratio of 0.688. The most common adverse events were upper respiratory tract infection, nasopharyngitis, diarrhoea and alopecia, and adverse events leading to treatment discontinuation were less frequent with remibrutinib, at 3.1%, than with teriflunomide, at 5.8%, with the authors reporting a safety profile consistent with other indications, including no liver safety concerns. The authors interpreted remibrutinib as superior to teriflunomide while maintaining a favourable safety profile, supporting it as a potential new oral treatment option, and the trials were funded by Novartis and remained ongoing and not recruiting at publication.

Why it matters: This is a clear phase 3, active comparator example for students, covering relapse rate as an endpoint, cross trial consistency, disability and MRI context, and how safety signals are weighed alongside efficacy for a central nervous system penetrant Bruton tyrosine kinase inhibitor.

Source: The Lancet, 23 October 2026

South Asia

Pakistan confirms seventh polio case of 2026 in Karachi East

Pakistan's National Emergency Operations Center for Polio Eradication confirmed a case in a six month old boy from Jamali Colony in Karachi East District, Sindh, on 19 October 2026. The case was detected through the polio surveillance network and confirmed by the Regional Reference Laboratory for Polio Eradication at the National Institute of Health in Islamabad. It was the first reported case in Karachi since December 2024, although environmental detections had continued in the city during the year. Of the seven cases reported in Pakistan in 2026, five were from Khyber Pakhtunkhwa and two were from Sindh. A case investigation was launched, and a further vaccination round was scheduled for 2 to 8 November across 97 districts, including all districts of Karachi, with the aim of protecting nearly 24 million children.

Why it matters: This shows students why surveillance, environmental monitoring and repeated campaigns remain central to eradication in the last endemic settings, and why a single urban case can signal wider transmission.

Source: Pakistan National Emergency Operations Center for Polio Eradication, 19 October 2026

Bangladesh strengthens its frontline health emergency workforce

Bangladesh, led by the Institute of Epidemiology, Disease Control and Research and supported by the Pandemic Fund and the World Health Organization, reported progress on three connected workforce initiatives during 2026. A first One Health field epidemiology mentorship workshop in Gazipur from 27 to 30 September brought together 29 mentors, field epidemiologists and stakeholders from human, animal and environmental health. In July, 47 representatives from 21 organisations in Dhaka mapped the community health workforce and identified ways to improve coordination, training and emergency preparedness. Bangladesh also finalised a national adaptation of the WHO Global Laboratory Leadership Programme after a workshop on 28 and 29 September with 16 experts, with the programme now being integrated into the national laboratory system. The work sits alongside a National Action Plan for Health Security for 2026 to 2030 and a National IHR Authority established in July 2026.

Why it matters: This is a clear example of One Health in practice, linking community workers, field epidemiologists and laboratory leaders, and of how workforce capacity underpins early detection and response.

Source: WHO Bangladesh, 19 October 2026

India grants marketing authorisation for fitusiran in haemophilia

The Central Drugs Standard Control Organisation, under the Drugs Controller General of India, granted marketing authorisation to Sanofi's Qfitlia (fitusiran) on 21 October 2026. The authorisation covers routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents aged 12 years and older living with haemophilia A or B, with or without factor VIII or IX inhibitors. Fitusiran is described as the first antithrombin lowering therapy authorised in India for this preventive use, working by a different mechanism from conventional factor replacement. The approval was based on data from the ATLAS phase 3 clinical development programme, which reported clinically meaningful bleed protection measured by annualised bleeding rates across groups with and without inhibitors. Sanofi cited an estimated haemophilia population of about 140,000 in India, with about 28,900 people registered.

Why it matters: This introduces pharmacy students to a rebalancing approach to haemophilia care, to inhibitor status as a key clinical distinction, and to how phase 3 evidence supports a national regulatory decision.

Source: Sanofi India, 21 October 2026

India steps up the move away from mercury based medical devices

WHO India reported on 22 October 2026 that India is accelerating efforts to remove mercury containing medical thermometers and blood pressure monitors from health care services by 2030. A technical mission involving the Ministry of Health and Family Welfare, the Ministry of Environment, Forest and Climate Change, WHO, the United Nations Environment Programme, the Global Environment Facility, the Minamata Secretariat and state officers met in New Delhi from 28 to 30 September 2026 to review progress. Fourteen states had completed inventories and assessments of mercury based devices, and 12 states had issued phase out orders. Delhi, Punjab, Manipur, Sikkim, Goa, Haryana, Ladakh, Chandigarh and the Andaman and Nicobar Islands had eliminated their use in public health services. Thirty state nominated nodal officers received online training on the national strategy, and systems for segregation, safe collection, temporary storage, safe transport and safe disposal were to be established by late 2027.

Why it matters: This links device selection, occupational safety and waste management to environmental health, and shows how a treaty commitment is translated into procurement, training and disposal practice.

Source: WHO India, 22 October 2026

Bangladesh assesses medicine supply chains to improve access to essential medicines

The Directorate General of Health Services in Bangladesh, with WHO support, carried out a field assessment across 16 public health facilities between 13 September and 5 October 2026 to identify gaps in medicine supply management. Teams visited district hospitals and upazila health complexes in Khulna, Sunamganj, Rajshahi, Khagrachari, Bhola and Nilphamari, reviewing stocks against records, storage conditions and the use of logistics information. The assessment examined the electronic Logistics Management Information System, which has been introduced progressively since 2021 and expanded to 84 facilities in nine pilot districts, as well as central supply operations and selected disease programmes. Preliminary observations pointed to shortages of equipment and trained personnel, parallel manual and electronic reporting, discrepancies between recorded and physical stocks, inadequate storage and monitoring, and procurement delays. A detailed report is being prepared, with preliminary recommendations covering training, storage infrastructure, standardised medicine lists and reduced duplicate reporting.

Why it matters: This shows students that medicine access depends on supply chain data, storage and workforce capacity, not only on product availability, and why good pharmacy practice matters at facility level.

Source: WHO Bangladesh, 25 October 2026

Europe

Only 3 stories met the bar this week.

MHRA authorises plozasiran for rare high triglyceride condition

The Medicines and Healthcare products Regulatory Agency authorised plozasiran, sold as Redemplo, on 19 October 2026 for adults with familial chylomicronaemia syndrome, alongside a low-fat diet. Familial chylomicronaemia syndrome is a rare condition that causes abnormally high blood triglyceride levels, which can lead to pancreatitis and severe abdominal pain. Plozasiran works by blocking production of apolipoprotein C3, a liver protein that slows the breakdown of fats, and lower production of this protein helps lower blood triglyceride levels. Authorisation was supported by a main study of 75 adults, all following a controlled diet, with 50 receiving plozasiran and 25 receiving placebo. After 10 months, median triglyceride levels fell by around 80% in the plozasiran group, compared with 17% in the placebo group, and fewer acute pancreatitis episodes were recorded with plozasiran.

Why it matters: It gives pharmacy and healthcare students a clear example of a targeted rare disease therapy, an International Recognition Procedure authorisation using the European Medicines Agency as reference regulator, and a trial result based on a surrogate marker with a clinical complication outcome.

Source: MHRA (GOV.UK), 19 October 2026

Government confirms long term recognition of CE marked medical devices in Great Britain

The government confirmed on 21 October 2026 that it will continue to accept CE marked medical devices and in vitro diagnostic devices on a long term basis in Great Britain. The decision followed a public consultation from 16 February to 10 April 2026, which received more than 1,000 responses from patients, healthcare organisations, industry and others. Under the decision, the United Kingdom will not require an additional approval route for devices already approved for the European Union market, avoiding duplication for manufacturers and helping maintain stable supply and patient access. More than 90% of medical devices registered for use in Great Britain currently carry a CE mark, meaning they have been assessed and approved for the European market. The UKCA marking route continues as the domestic approval pathway, while the Medicines and Healthcare products Regulatory Agency will continue to oversee all devices on the United Kingdom market, including through Yellow Card safety monitoring.

Why it matters: It is a major post Brexit regulatory policy decision for students, linking device regulation, supply resilience, and post market surveillance, and it affects everyday technologies from insulin pumps and diagnostic tests to replacement joints and surgical equipment.

Source: MHRA and Department of Health and Social Care (GOV.UK), 21 October 2026

MHRA approves oral icotrokinra treatment for moderate to severe plaque psoriasis

The Medicines and Healthcare products Regulatory Agency approved icotrokinra hydrochloride, sold as Icotyde, on 23 October 2026 for moderate to severe plaque psoriasis. The authorisation covers adults and adolescents aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy, and it was granted to Janssen-Cilag Limited. Plaque psoriasis is an inflammatory condition that causes red, scaly and often itchy or painful patches of skin, and it can affect areas including the scalp, genitals, hands and feet, as well as the nails. Approval was supported by data from four Phase 3 clinical trials involving 2,500 people with moderate to severe plaque psoriasis, including 72 adolescents aged 12 to under 18 years weighing at least 40 kg. At week 16, all four studies demonstrated efficacy compared with placebo in the populations studied, and the medicine works by selectively binding to and blocking the IL-23 receptor, which is involved in inflammatory and immune responses.

Why it matters: It illustrates an oral targeted therapy for a common chronic inflammatory skin condition, the use of adolescent data within an adult led trial programme, and routine post authorisation safety monitoring through the Yellow Card scheme.

Source: MHRA (GOV.UK), 23 October 2026

North America

Only 3 stories met the bar this week.

FDA grants accelerated approval to ravulizumab for proteinuria in primary IgA nephropathy

The US Food and Drug Administration approved a new indication for ravulizumab, sold as Ultomiris, in an approval letter signed on 21 October 2026. The indication was to reduce proteinuria in adults with primary immunoglobulin A nephropathy who were at risk of disease progression. The approval was granted under accelerated approval regulations, so it was based on a surrogate outcome rather than a confirmed long term kidney outcome at that stage. The letter required an adequate and well controlled confirmatory trial to verify and describe clinical benefit, with trial completion listed as June 2028 and a final report due in October 2028. The letter also approved modifications to the shared Ultomiris and Soliris risk evaluation and mitigation strategy to reflect the new indication.

Why it matters: It is a clear teaching example of accelerated approval, surrogate endpoints, and postmarketing confirmatory trials in nephrology.

Source: FDA, 21 October 2026

CDC and FDA investigate multistate Salmonella outbreak linked to Virginia oysters

The US Centers for Disease Control and Prevention published an investigation notice on 19 October 2026 into a multistate outbreak of Salmonella Telelkebir infections linked to raw oysters from the Little Wicomico River in Virginia. Illnesses in the initial notice started between 29 May and 14 September 2026. Of 13 people interviewed, 10 reported eating raw oysters in the week before illness, a proportion far higher than in the FoodNet population survey. Traceback for seven of those people pointed to a common source, oysters harvested by the Little Wicomico Oyster Company. The FDA update for 19 October 2026 described a cluster of 27 illnesses under investigation, a recall of oysters harvested between 18 September and 8 October 2026, and temporary closure of the river to shellfish harvesting from 9 October 2026.

Why it matters: It demonstrates outbreak investigation methods, including interviews, whole genome sequencing, traceback, and coordinated recall and closure actions.

Source: CDC, 19 October 2026

NIH reports early results for invikafusp alfa in treatment resistant solid tumours

The US National Institutes of Health reported on 23 October 2026 early results from the first human trial of invikafusp alfa, known as invika, in solid tumours that had resisted standard immunotherapy. The drug was designed to activate only a narrow subset of tumour infiltrating T cells, rather than T cells broadly, with the aim of driving anti-tumour activity while limiting severe side effects. In phase 1, participants received varying doses every two weeks to establish safety and an optimal dose, before phase 2 testing at that dose. Of 27 participants treated at the optimal dose, disease did not progress in 16 participants (59.3%), and four participants (14.8%) had reductions of more than 30% in targeted tumour size. Flu-like side effects were reported and were generally manageable with additional medication and supportive care, but the authors stressed that these results were early.

Why it matters: It illustrates selective T cell agonism, dose finding, and how early phase results are interpreted cautiously before larger trials.

Source: NIH, 23 October 2026

Africa

Nigeria confirms imported Bundibugyo virus disease case in Abuja

Nigeria confirmed one imported case of Ebola disease caused by Bundibugyo virus in the Federal Capital Territory, making it the fifth country to detect the virus since the outbreak was declared in the Democratic Republic of the Congo on 15 May 2026. According to the Federal Ministry of Health and Social Welfare, the patient was a woman with recent travel history to Uganda, whose symptoms began on 7 October, four days after arrival in Nigeria. She sought care at a private health facility in Abuja on 11 October, and laboratory testing confirmed Bundibugyo virus on 20 October. She was in isolation and receiving medical care while investigations continued into the likely source of infection and her full travel and exposure history. The ministry reported that 44 contacts had been identified and were being monitored, the Nigeria Centre for Disease Control and Prevention had activated its incident management system, and WHO and partners were supporting case investigation, contact tracing, infection prevention and control, and supplies including personal protective equipment.

Why it matters: It shows how imported cases are detected, confirmed and contained, and why contact tracing, infection prevention and control, and readiness in private facilities are central skills for pharmacy and healthcare students.

Source: WHO Regional Office for Africa, 21 October 2026

Africa CDC convenes African health ministers over spreading Ebola outbreak

Africa CDC announced on 21 October 2026 that it would convene a high level virtual meeting of African Ministers of Health on 28 October 2026, as the Bundibugyo virus outbreak continued in the Democratic Republic of the Congo and cases had also been reported in Kenya and Nigeria. The agency said the spread across Central, Eastern and Western Africa demanded urgent and coordinated action, five months into a response that followed its declaration of a Public Health Emergency of Continental Security on 18 May 2026. The ministerial meeting was intended to assess the situation, strengthen coordination across borders, accelerate support to affected countries and reinforce preparedness across the continent. Africa CDC also said the meeting was expected to inform preparations for a Heads of State and Government Summit under the leadership of Burundi, as Chairperson of the African Union. It called on Member States to strengthen vigilance, surveillance, cross border cooperation, community engagement and protection of frontline health workers.

Why it matters: It illustrates continental outbreak governance in practice, including how political coordination, surveillance and cross border cooperation support the clinical and public health response.

Source: Africa CDC, 21 October 2026

African Union Member States validate continental health data governance framework

African Union Member States validated the African Continental Health Data Governance Framework in Addis Ababa on 22 October 2026, paving the way for what Africa CDC described as Africa's first common continental approach to the lawful, secure, ethical and sovereign governance of health data. The framework is intended to help countries develop national legislation, policies and governance systems, while enabling secure data sharing to improve disease surveillance, public health responses and healthcare delivery. It builds on existing African Union instruments, including the Malabo Convention, the AU Data Policy Framework and the Digital Transformation Strategy for Africa. A proposed federated approach would allow countries to share information securely across borders without relinquishing oversight of their national health data systems. Africa CDC said it would finalise the framework on the basis of agreed amendments and advance it through African Union policy processes, with consideration anticipated in 2027 and implementation then led by Member States.

Why it matters: For students, it links digital health, data protection and surveillance, showing how shared rules can support outbreak response while keeping control of national health data with governments.

Source: Africa CDC, 22 October 2026

First participant vaccinated in Tumaini Bundibugyo vaccine trial in Bunia

The first participant was vaccinated on 23 October 2026 in Bunia, in the Democratic Republic of the Congo, marking the start of Tumaini, a pivotal Phase 2/3 clinical trial of vaccine candidates against Bundibugyo virus. Tumaini, meaning hope in Swahili, is an adaptive platform trial that can evaluate several vaccine candidates within a single framework, using ring vaccination focused on contacts at high risk of infection. There is currently no approved vaccine to protect against Bundibugyo virus, and the trial aims to evaluate safety, immune response and efficacy. The first candidate to enter the trial is Ervebo, which is currently licensed to prevent Ebola virus disease, while two Bundibugyo specific candidates under development by Moderna and by the University of Oxford in collaboration with Serum Institute of India were being prepared to enter shortly. The trial is co-led and co-sponsored by the Institut National de Recherche Biomédicale and the University of Antwerp, with national leadership and oversight from the Democratic Republic of the Congo Ministry of Health. CEPI reported 9,552 cases and 4,602 deaths confirmed in the Democratic Republic of the Congo as of 21 October 2026.

Why it matters: It is a landmark example of outbreak research, showing the difference between a licensed product for one virus species and evidence still being gathered for another, and why trial design and inclusion matter in an emergency.

Source: CEPI, 23 October 2026

Uganda expands community malaria testing and treatment to all age groups

Uganda is expanding community based malaria diagnosis and treatment beyond children under five to people of all ages, through Village Health Teams and Community Health Extension Workers trained and equipped to test people in their communities using rapid diagnostic tests and provide free treatment locally. The Ministry of Health led initiative responds to a longstanding problem in rural areas, where older children and adults often had to travel long distances to a health facility to find out whether they had malaria and begin treatment. WHO reported that approximately 85,000 Village Health Team members provide community based health services across Uganda, and that extending services to all age groups helps address a larger reservoir of infection while improving equity in access to care. The expansion forms part of Uganda's 24-2 Hours Initiative, which aims for malaria diagnosis and treatment within 24 hours of symptom onset and lifesaving pre-referral treatment for severe malaria within two hours. WHO also reported that malaria related deaths in Uganda have fallen by more than 50 percent since 2000, while an estimated 13.2 million cases were reported in 2025 and between 16,000 and 20,000 people died from malaria in the same year.

Why it matters: It demonstrates community pharmacy and primary care principles in action, including timely diagnosis, access close to home, and the role of trained community health workers in reducing delays to care.

Source: WHO Regional Office for Africa, 23 October 2026

Older: Week ending 18 October 2026 →  ·  All Global Health News

Every story on this page was verified on its original source page. Coverage is pharma, medical, healthcare and community health only; no politics or finance.